CDR2 and cancer: In 2021, experts classified anti-Yo PCD as a rapidly progressive cerebellar syndrome with a high-risk phenotype due to its >90% cancer association and 80% antibody detection rate; when cancer is present, it is categorized as a definitive paraneoplastic neurologic syndrome (PNS), based on clinical and antibody criteria [29,35].